TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
5.39
+0.04 (0.75%)
At close: Oct 11, 2024, 4:00 PM
5.65
+0.26 (4.82%)
After-hours: Oct 11, 2024, 5:41 PM EDT
TScan Therapeutics Employees
TScan Therapeutics had 154 employees as of December 31, 2023. The number of employees increased by 16 or 11.59% compared to the previous year.
Employees
154
Change (1Y)
16
Growth (1Y)
11.59%
Revenue / Employee
$79,221
Profits / Employee
-$678,006
Market Cap
285.53M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 154 | 16 | 11.59% |
Dec 31, 2022 | 138 | 33 | 31.43% |
Dec 31, 2021 | 105 | 47 | 81.03% |
Dec 31, 2020 | 58 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Sight Sciences | 214 |
Alpha Teknova | 211 |
Akebia Therapeutics | 167 |
Heron Therapeutics | 126 |
Sanara MedTech | 108 |
Atea Pharmaceuticals | 75 |
Ocugen | 65 |
PepGen | 64 |
TCRX News
- 9 days ago - TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting - GlobeNewsWire
- 6 weeks ago - TScan Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology - Seeking Alpha
- 2 months ago - TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - TScan Therapeutics Announces Updates to its Board of Directors - GlobeNewsWire
- 4 months ago - TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 4 months ago - TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies - GlobeNewsWire
- 5 months ago - TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire